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The induction of alloantigen-specific immune tolerance is the “Holy-Grail” in transplantation. Although it had been
previously demonstrated that transient depletion of T cells through apoptosis could lead to long-term immune
tolerance, the underlying mechanism responsible for this tolerance induction and maintenance was unknown. In this
short article, a novel mechanism for long-term immune tolerance via transient T cell apoptosis will be discussed, based
on our recent findings in a CD3-specific antibody treatment-induced immune tolerance mouse model. Transforming
growth factor-β, which is produced by immature dendritic cells whilst they phagocytose apoptotic T cells and by
macrophages, plays an important role in initiating long-term immune tolerance. A possible model of how
allospecific-immune tolerance can be induced in order to prevent allograft rejection in transplantation will be
also proposed.Introduction
Despite the majority of the cells in the body being healthy
and functional, there are still considerable numbers of cells
dying through apoptosis every day. The death of a cell and
the release of its contents could lead to tissue damage and
is associated with the risk of development of inflammation
and autoimmunity if the apoptotic/dead cells are left un-
checked or uncleared. However, very few people develop
symptoms of autoimmunity and/or chronic inflammation.
The most plausible explanation to this mystery is that
apoptotic cells are rapidly and sufficiently engulfed and
digested by phagocytes, such as macrophages. It has long
been believed that this “passive” phagocytosis and clear-
ance of apoptotic cells by macrophages was the sole mech-
anism that prevented the body from potential damage
caused by the release of the contents of late apoptotic cells
(when cell membrane of apoptotic cells is damaged). Al-
though the idea of “passive phagocytosis” is an established
fact in the biology of apoptosis, it may represent only the
tip of the iceberg. Recent advances in our understanding of
apoptosis show that “active suppression” may also be in-
volved and this accounts for the “quiescent” and “immuno-* Correspondence: wchen@dir.nidcr.nih.gov
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totic cells. This concept of “active suppression” is sup-
ported by recent findings showing that macrophages
produce and release the immunoregulatory cytokines
transforming growth factor-beta (TGF-β) and interleukin
IL-10 (IL-10) [1–4] when they contact, engulf, and digest
apoptotic cells in cell culture. These immunoregulatory cy-
tokines may in turn participate in preventing and/or sup-
pressing the possible deleterious after-effects of cell death
and of phagocytosis of apoptotic cells. Although this piece
of in vitro evidence provided a new clue that helped us
understand this “immuno-quiescence” phenomenon asso-
ciated with apoptotic cell clearance, it was unknown
whether this process occurs in vivo, and more importantly,
if it is involved in the prevention and suppression of dis-
eases such as transplant rejection and autoimmunity.
CD4+ CD25+ Foxp3+ regulatory cells (Treg cells) are
instrumental in the induction and maintenance of per-
ipheral immune tolerance [5–10] and of immune toler-
ance in transplantation [11–13]. Despite the fact that the
majority of CD4+ Foxp3+ T cells are developed in the thy-
mus as so called “natural” Treg cells, compelling evi-
dence has suggests that TGF-β, in the context of T cell
receptor engagement, induces Foxp3 expression from
naïve CD4+ Foxp3– peripheral T cells and converts themticle distributed under the terms of the Creative Commons Attribution License
which permits unrestricted use, distribution, and reproduction in any medium,
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cells [14]. These adoptive Treg cells are functionally and
phenotypically indistinguishable from the natural Treg
cells. IL-2 is a critical cytokine in the induction and ex-
pansion of the adoptive Treg cells [15, 16]. The conver-
sion to adoptive Treg cells also occurs in vivo, for which
TGF-β signaling is required [17, 18]. Despite the general
consensus that TGF-β is absolutely required for the Treg
cell generation, it remains largely unknown what types of
immune cells are the major source of TGF-β in vivo.
Foxp3+ Treg cells themselves could be a cellular source of
TGF-β [5, 19–21], which then “infectiously” converts naïve
CD4+ T cells into adoptive Foxp3+ Treg cells [13, 22]. In-
deed, macrophages [2, 23] and immature dendritic cells
(iDCs) [24, 25] produce TGF-β. A critical question to be
answered is how these phagocytes are triggered to release
TGF-β in vivo and thereby consequently contributing to
Treg cell generation and immune tolerance.
Immune tolerance associated with T cell depletion
It is well established that transient T cell depletion
(largely through apoptosis) induces long-term immune
tolerance. A CD3-specific antibody (OKT3) was the first
monoclonal antibody that was used as an immunosup-
pressive agent in clinical renal transplantation [26] and
has been in use for almost three decades [27]. Monoclo-
nal antibodies against murine CD3 (e.g. Clone 145-2c11)
have also been used in several animal models of trans-
plantation and autoimmune diseases [27, 28]. Monoclo-
nal antibodies to both human and mouse CD3-specific
antigen rapidly and efficiently deplete large numbers of
T cells (about of 50 % of the T cell population) in the re-
cipients, is largely via induction of apoptosis. Adminis-
tration of a CD3-specific antibody injection resulted in
short term immunosuppression followed by long-term
immune tolerance, although the initial antibody injection
induced a transient “flu-like” side effect [28].
Besides CD3-specific antibodies, there have been sev-
eral other antibodies used to deplete T cells in order to
induce immune tolerance. In 1989, Waldmann’s group
showed that depletion of CD4+ T cells after exposure to
certain antigens resulted in long-term specific immune
tolerance in a study in mice [29]. Steinman and his col-
leagues treated mice with an antibody to CD4, which
prevented the development of experimental autoimmune
encephalomyelitis (EAE); in animals already paralyzed,
administration of the same antibody reversed the EAE
[30]. Recently, it was demonstrated in mice that selective
depletion of alloantigen T effector cells via blockade of
co-stimulatory molecules plus administration of rapamy-
cin permitted acceptance of the allograft [31, 32]. The
allograft was not rejected despite the complete recovery
of peripheral T cells after the treatment was stopped.
This raised an important question as to why the newlymaturing T cells did not replace these deleted T cells
and did not reject the graft or initiate a new wave of in-
flammation after cessation of the treatment [33]. Taken
together, all these data suggest that there is a common
underlying mechanism of immune tolerance that follows
after apoptosis of T cells. The question is: how do apop-
totic cells trigger the immune system to become toler-
ant, and what are the mediator(s) that link T cell
apoptosis to long-term immune tolerance?
The role of macrophage-derived TGF-β in apoptotic
cell-mediated immune tolerance
We used CD3-specific antibody-induced tolerance in
mice as a model to study the mechanisms of apoptotic
cell-mediated immune tolerance. Based on the observa-
tions that a CD3-specific antibody injection induced T
cell apoptosis [28] and that macrophages produce TGF-
β after phagocytosis of apoptotic cells in cell culture [1,
2, 34], we hypothesized that the CD3-specific antibody
might induce TGF-β production in vivo through clearing
(phagocytosis) of apoptotic T cells. Indeed, intact CD3-
specific antibody treatment increased total levels of sys-
temic TGF-β in normal mice [34]. These elevated levels
of systemic TGF-β can last for at least a few days. Not-
ably, the kinetics of the increase in circulating TGF-β
levels was different from that of inflammatory cytokines
[28]. While the levels of circulating inflammatory cyto-
kines, including tumor necrosis factor (TNF), interferon
(IFN)-γ and IL-2, reached a peak at about 90 min and
largely dropped off to almost zero by 6 h after the initial
CD3-specific antibody injection [35], the peak in the
total TGF-β in the circulation was not observed until
about 24 h after the initial injection [34]. The difference in
the kinetics between TGF-β and other inflammatory cyto-
kines suggests that they may be derived from different cel-
lular sources. Indeed, circulating TNF was produced
exclusively by T cells following CD3- specific antibody in-
jection [35]. Whereas TGF-β was mainly produced by
phagocytes, particularly macrophages and immature
dendritic cells [34] (discussed below), as demonstrated
in a study where depletion of these phagocytes with
clodronate-loaded liposome abrogated the increase in
TGF-β in animals treated with a CD3-specific antibody.
This production of TGF-β by macrophages is triggered
largely by apoptotic T cells (in which apoptosis was in-
duced by CD3-specific antibodies). Further supporting
evidence comes from the observation that macrophages
could very efficiently contact, engulf and ingest apop-
totic T cells not only in cell culture, but also in vivo
[34]. Direct examination of the macrophages ex vivo
24 h after the CD3-specific antibody injection, revealed
that they expressed significantly higher levels of a
membrane-bound latent-form of TGF-β (LAP-TGF-β)
than untreated macrophages [34]. In addition, injection
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ImmunoglobulinG3) that caused substantially less T
cell apoptosis failed to result in a significant increase in
systemic TGF-β levels [36, 37]. The evidence collect-
ively identifies macrophages as a key cellular source for
the increase in TGF-β following CD3-specific antibody
induction of T cell apoptosis.
Immature dendritic cells in apoptotic cell-mediated
immune tolerance
Notably, iDCs also produce TGF-β through the phago-
cytosis of apoptotic cells and thus contribute to apop-
totic cell-linked immune tolerance. iDCs express lower
levels of the co-stimulatory molecules CD80, CD86 and
MHC II and do not express CD83 [38]. In contrast to
mature DCs, iDCs are incapable of initiating effective
Th1 and Th2 responses, but they can induce T cell toler-
ance. A unique feature of iDCs is their ability to engulf
and digest apoptotic cells. Although previous studies
emphasized an antigen-presenting function of iDCs after
uptake of apoptotic cells, none examined whether the di-
gestion of apoptotic cells affected their function of indu-
cing adoptive immune responses. Recently, it has been
reported that iDCs express TGF-β consequently result-
ing in the conversion of naïve CD4+ T cells into Foxp3+
Treg cells [25, 39, 40]. We found that exposure of iDCs
to apoptotic cells substantially increased their TGF-β se-
cretion and consequently strengthened their ability to
convert naïve CD4+ T cells into Foxp3+ Treg cells [34].
This occurred in cell culture as well as in vivo; in mice,
iDCs potently engulf apoptotic T cells and selective de-
pletion of iDCs with clodronate-liposomes interferes
with this increase in CD4+ Foxp3+ Treg cells induced by
the CD3-specific antibody. Thus, it would be reasonable
to envision that iDCs actively participate in the induc-
tion of CD4+ Foxp3+ Treg cells and immune tolerance
because of the TGF-β they produce after ingestion of
apoptotic cells.
A link between apoptotic cells and the upregulation of
CD4+ Foxp3+ Treg cells in vivo
The fact that both macrophages and iDCs produce TGF-
β upon digestion of apoptotic cells and convert naïve
CD4+ T cells into Foxp3+ Treg cells raises the possibility
that this process may also influence the frequency of
Foxp3+ Treg cells in vivo. Indeed, CD3- specific anti-
body treatment increases the frequency of Foxp3+ CD4+
Treg cells in mice. As early as 24 h after antibody injec-
tion, the relative percentage of Foxp3+ Treg cells in the
CD4+ T cell compartment had already increased in the
peripheral lymphoid tissues and blood [34]. It is unclear
whether this immediate increase was associated with the
relative resistance to death of natural Treg cells in re-
sponse to a CD3-specific antibody. Intriguingly, by fourto ten days and even one to two months after the CD3-
antibody injection, the frequency of CD4+ Foxp3+ Treg
cells is still substantially higher than that in the un-
treated mice (34 and unpublished data). This indicates
that the increase in the number of Treg cells may also be
attributable to a population converted from naïve CD4+ T
cells, although a lymphopenic-driven expansion of existing
Treg cells caused by CD3-antibody treatment may also be
involved. Notably, this increase in CD4+ Foxp3+ Treg
cells is associated with the endogenous macrophages
and iDCs, because depletion of these phagocytes abro-
gated the upregulation of Treg cells, accompanied by a
decrease in TGF-β levels [34]. Therefore, it is conceiv-
able that the apoptotic T cells trigger macrophages and
iDCs to produce TGF-β, which in turn generates CD4+
Foxp3+ Treg cells. The increase in the ratio between
Foxp3+ Treg cells and T effector cells is likely to be the
major operating force in maintaining long-term im-
mune tolerance.
A critical function of phagocyte-derived TGF-β in the
prevention and treatment of chronic inflammation
The apoptotic T cell-phagocyte that mediated immune
tolerance was also tested and proven to be functional in
the prevention and treatment of autoimmune diseases in
an animal model of autoimmune disease - EAE. Firstly,
treatment of mice with a CD3- specific antibody before
the pathogenic peptide immunization effectively pre-
vented the onset and development of EAE in myelin
oligodendrocyte glycoprotein-induced EAE in C57BL/6
mice [34]. In this animal model, one might argue that
the treated mice are still in a state of T cell deficiency
four to five days after the CD3-specific antibody injec-
tion, and thus the immune unresponsiveness might be
due to the lack of sufficient numbers of T cells. While
this argument is reasonable, the mice with the same
CD3-specific treatment plus phagocyte depletion had a
similar number of T cells as the mice treated with the
antibody alone, but exhibited a complete reversal of the
suppression of EAE. A more striking effect was observed
in the “treatment” experiment. The SJL mice were immu-
nized with the proteolipid protein peptide PLP139-151 in
the presence of complete freund adjuvant to establish EAE
and were then treated with CD3-specific antibodies.
The CD3-specific antibody treatment led to a dramatic
improvement of the disease course in this relapsing-
remitting EAE, demonstrated by the delay of the first re-
lapse, a decrease in the severity of the clinical score, and
a reduction in the frequency of relapses [34]. The benefit
of the CD3-specific antibody treatment was long lasting
and was associated with an immunoregulatory dominant
status in the mice. Evidence in support of this conclusion
is the upregulation of the frequency of CD4+ Foxp3+ Treg
cells in the spleen and in the target central nervous tissues
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Treg cells to CD25+ Foxp3– CD4+ T effector cells or to
Th17 or Th1 cells. Significantly, the therapeutic effect was
completely reversed by pre-depletion of the phagocytes or
neutralization of TGF-β with a blocking antibody before
the CD3-specific antibody treatment.
Immune tolerance induced by apoptotic cells with other
regimens
In addition to antibody-mediated depletion of T cells, other
regimens and means have been shown to induce long-term
immune tolerance through induction of apoptosis. In this
regard, it has been shown that an infusion of ethylene
carbodiimide-treated donor splenic antigen-presenting
cells results in indefinite survival of allogeneic islet grafts
[41]. The mechanisms for ethylene carbodiimide-treated
cell induced tolerance may involve the apoptosis-mediated
TGF-β pathway, because ethylene carbodiimide induces
the cells to undergo rapid apoptosis, and the tolerance can
be completely abrogated by the neutralization of TGF-β or
depletion of CD4+ CD25+ Foxp3+ Treg cells. Moreover,
intravenous infusion of apoptotic splenic cells induced
TGF-β-dependent Treg cell generation that in turn facili-
tated allogeneic bone marrow engraftment and delayed the
onset of graft-versus-host disease [42]. Lastly, extracorpor-
eal photochemotherapy (ECP) (a therapeutic approach
used to treat severe graft-versus-host disease) generates
significant numbers of apoptotic leukocytes [43] and is also
known to induce Treg cells in vivo [44]. Whether apoptotic
cell removal by phagocytes is involved in this generation of
Treg cells remains to be determined.
Besides T cells, depletion of B cells or plasma cells also
leads to the control of the deleterious immune responseFig. 1 A proposed model to induce alloantigen-specific immune tolerance fo
of apoptotic cells, creation of an immunoregulatory milieu and generation of
generated, the allograft can be transplanted and should be accepted indefinit
T, T cell; TGF-β, transforming-growth factor-βand this mechanism has been recently applied to the treat-
ment of autoimmune diseases. Although these studies em-
phasized the depletion of certain type(s) of pathogenic B
cells to achieve a therapeutic effect, it would not be impos-
sible that the B cell depletion might also lead to similar
apoptosis/phagocytosis‐mediated immunoregulatory mech-
anisms as described for T cell depletion. It would be inter-
esting to investigate if this was the case because this would
provide another option to achieve immune tolerance in
transplantation. However, it should be pointed out that T
cell receptor engagement is required to convert naïve T
cells into Treg cells in addition to TGF-β secreted by
phagocytes clearing apoptotic cells. Thus, whether B cell
depletion could induce Treg cells may also depend on the
T cell receptor engagement of the antigen-specific T cells.
Manipulation of apoptotic cell-mediated immune tolerance:
implications for transplantation
Apoptotic cell-linked immune tolerance has implica-
tions for the prevention and inhibition of transplant re-
jection. We propose using allograft transplantation as
the therapeutic model for demonstrating how accept-
ance of an allograft can be achieved by use of apoptotic
T cell-mediated immune tolerance. The model can be
divided into three steps: induction of apoptotic cells,
creation of an immunoregulatory milieu and generation
of alloantigen-specific Treg cells (Fig. 1).
Induction of apoptotic cells
The induction of T cell apoptosis can be divided into two
pathways, non-selective and selective. The use of anti-
bodies against T cells or certain subsets of T cells (by using
for example CD3-, CD4- or CD8-specific antibodies),r transplantation. The model can be divided into three steps, i.e. induction
alloantigen-specific Treg cells. Once the alloantigen-specific Treg cells are
ely. iDC: immature dendritic cells; IL-10, interleukin-10; Mo, macrophage;
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logical reagents and radioactive irradiation may also acti-
vate the non-selective pathway. The advantage of the
nonselective pathway is that it can induce high numbers of
apoptotic T cells. It could facilitate creating a stronger im-
munoregulatory microenvironment through large amounts
of TGF-β production by phagocytosis of the apoptotic
cells. The disadvantage of this non-selective pathway is that
apoptosis of cells fighting infection and tumor cells would
also be induced, although it remains unknown if this tran-
sient depletion affects the capacity of immune defense. The
selective induction of apoptosis can be achieved by the
depletion of particular subpopulations of T cells that
respond to a specific alloantigen. A blockade of co-
stimulatory molecules plus treatment with rapamycin
together leading to depletion of alloantigen-responsive
T cells should belong to this pathway [31, 32]. The ad-
vantage of the selective pathway is that other types of T
cells are not affected, minimizing the potential side ef-
fects. The disadvantage with the selective pathway,
however, is that it may be difficult to obtain sufficient
numbers of apoptotic cells necessary to initiate the im-
munoregulatory milieu. Ideally, “apoptosis induction”
should be transient and as specific as possible. It should
obtain sufficient numbers of apoptotic cells but without
exceeding the phagocytotic capacity of the macro-
phages and iDCs.
Creation of an immunoregulatory milieu
The uptake and digestion of apoptotic T cells by macro-
phages and iDCs trigger these phagocytes to produce im-
munoregulatory cytokines such as TGF-β and/or IL-10
and other unknown factors to create an immunoregula-
tory milieu. Ideally, the quantities of TGF-β and IL-10
produced should be large enough (but not overly large)
to create the immunosuppressive milieu. The time
period of high levels of these cytokines should not last
too long, as both TGF-β and IL-10 are non-specific and
execute multiple effects. It is imperative to explore and
determine how long this “immunoregulatory milieu”
should last.
Generation of alloantigen-specific Treg cells
Once the immunoregulatory milieu is established, the
donor alloantigen should be introduced into the recipient
to induce alloantigen-specific Treg cells. This is because it
is more likely that the alloantigen specific T cells become
anergic or differentiate into Treg cells in response to the
donor alloantigen when in a TGF-βrich immunosuppres-
sive microenvironment. This step is critical to transform
the initial non-specific immunosuppressive steps into an
alloantigenspecific immune tolerance.
After the alloantigen-specific Treg cells have been gener-
ated, the donor allograft can be transplanted and should beaccepted within the host indefinitely because theoretically,
the allograft could continue to provide alloantigens to
maintain and expand the population of alloantigen-specific
Treg cells and/or to induce new alloantigen-specific Treg
cells [44]. It should be pointed out that induction and
maintenance of alloantigen-specific Treg cells is the key for
long-term “specific” tolerance. Although this proposed
model of immune tolerance is theoretically possible, much
work needs to be done before it is clinically applicable.
Concluding remarks
A transient but sufficient number of apoptotic cells can
induce a long-term immune tolerance. This process in-
volves the production of immunoregulatory cytokines,
and in particular TGF-β by the phagocytes that clear
apoptotic cells. These immunoregulatory cytokines in
turn help create an immunosuppressive microenviron-
ment under which alloantigen-specific T cells are aner-
gized or converted into alloantigen-specific Treg cells
rather than differentiating into Th1, Th2 or Th17 im-
mune inflammatory effectors. The induced alloantigen-
specific Treg cells will favor the acceptance of the donor
allograft from the same donor and protect the trans-
planted tissues from rejection. While this proposed
model to induce alloantigen-specific tolerance is attract-
ive and theoretically possible and would help us reach
the “Holy Grail” of transplantation, there is clearly still a
long way to go. For instance, interference by the im-
munosuppressive regimen (that is mandatory to avoid
acute graft rejection in clinical settings) should also be
considered [45]. By reinforcing our understanding of the
basic cellular and molecular mechanisms of immune tol-
erance, we could develop more effective therapy for the
patients who need transplantation.
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